Method for characterizing types of renal carcinoma and prognosis
AssigneeSloan-Kettering Institute for Cancer Research
InventorsNeil H. Bander, Carlos Cordon-Cardo, Connie L. Finstad, Willet F. Whitmore, Myron R. Melamed, Herbert F. Oettgen, Lloyd J. Old
Life of this patent
Estimating the term…
Abstract
Antigenic profiles of renal carcinoma specimans developed with panels of monoclonal antibodies derived from several different tissues serve as useful clinical indicators for cancer type, cancer subset as well as histiogenesis and prognosis indicators.
Claims6
A panel of monoclonal antibodies for determining types of renal cancer consisting of the monoclonal antibodies S4 (ATCC HB 8541), AJ8 (ATCC HB 8339), F23 (ATCC HB 8231), S23 (ATCC HB 8540), S27 (ATCC HB 8428), C26 (ATCC HB 8247), T16 (ATCC HB 8279), S22 (ATCC HB 8542), J143 (ATCC HB 8276), and V1 (ATCC HB 8424).
A panel of monoclonal antibodies for determining types of renal cancer consisting of the monoclonal antibodies S4 (ATCC HB 8541), AJ8 (ATCC HB 8339), F23 (ATCC HB 8231), S23 (ATCC HB 8540), S27(ATCC HB 8428), C26 (ATCC HB 8247), T16 (ATCC HB 8279), and S22 (ATCC HB 8542).
A panel of monoclonal antibodies for determining types of renal cancer consisting of the monoclonal antibodies S4 (ATCC HB 8451), F23 (ATCC HB 8231), S23 (ATCC HB 8540), S27 (ATCC HB 8428), S22 (ATCC HB 8542), and V1 (ATCC HB 8424).
Dependencies are inferred from the claim text.